Collaboration and license agreement with Genentech
As a validation of our ability to apply the mAb technology to disease areas outside of cancer, we entered in 2008 into a collaboration and license agreement with Genentech Inc., a member of the Roche Group, for the identification of antibody therapeutics against undisclosed infectious disease targets. Under the terms of the agreement, Genentech made an upfront payment to us as well as an equity investment in Symphogen. We are eligible for milestone payments exceeding DKK 700
million (USD >100 million) upon the successful achievement of certain research and development milestones, as well as single-digit royalties on worldwide sales.
Under the terms of the Genentech collaboration, Genentech is sponsoring the development of Sym009. Sym009 is currently in a Phase 1b clinical trial. The trial evaluates DSTA4637S, an investigational medicine containing Sym009 conjugated to an antibiotic agent, for the potential treatment of serious infections caused by Staphylococcus aureus (S.aureus) infections. This trial was initiated in July 2017 and is currently ongoing. Sym009 was originally discovered by isolating antibodies from individuals exposed to S.aureus using our patented Symplex® technology.